Sign in
Active, not recruitingPhase 2

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Key facts

Who runs it
Mirum Pharmaceuticals, Inc.
Where
Aurora, Boston, Cleveland, Coronado, Dallas, Detroit, Durham, Hixson, Houston, Jackson, Lakewood Rch, Los Angeles, Manhasset, Miami, Morrisville, Nashville, New York, Newport News, Philadelphia, Pittsburgh, Richmond, Rochester, Sacramento, Salt Lake City, San Francisco, Seattle, Tampa, and Washington D.C., United StatesSee the 34 sitesAlso in 13 other countries, 69 sites
Status
Active, not recruiting
Phase
Phase 2
People taking part
182 people enrolled
Started
18 Dec 2020
Expected to end
Mar 2028
Type of study
Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Volixibat
  • Placebo
Record updated
19 October 2026

Who can take part

Age
12 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Provide freely signed informed consent and assent (as applicable) and be willing to comply with all study visits and requirements through end of study, including the follow-up period
  • Subjects aged ≥12 years for eligible regions; otherwise ≥18 years
  • Confirmed diagnosis of large duct or small duct PSC based on American Association for the Study of Liver Disease (AASLD) guidelines
  • Pruritus associated with PSC as assessed by Adult ItchRO
  • Ursodeoxycholic acid (UDCA) and anti-pruritic medication use will be allowed if meeting additional criteria
  • Concomitant Inflammatory Bowel Disease (IBD) is allowed if meeting additional criteria

Who cannot take part

  • Evidence or clinical suspicion of decompensated cirrhosis, or a history of decompensation events
  • History of ileostomy or small bowel surgery/resection or other surgeries that may have disrupted the enterohepatic circulation
  • Evidence, history, or suspicion of other liver disease; PSC patients with AIH are not excluded
  • History of liver transplantation
  • Exceeding pre-defined biochemical values for alanine aminotransferase/aspartate aminotransferase (ALT/AST), estimated glomerular filtration rate (eGFR),serum creatinine (sCr), platelet count, international normalized ratio (INR) and total bilirubin
  • Pruritus associated with an etiology other than PSC
  • Bile duct stent or percutaneous bile duct drain placement, or balloon dilatation procedure of a stricture within 12 weeks of Screening

Where in United States

Also in 13 other countries, 69 sites

  • University of Colorado Anschutz Medical CampusAurora, United States
  • Beth Israel Deaconess Medical CenterBoston, United States
  • Cleveland ClinicCleveland, United States
  • Southern California Research CenterCoronado, United States
  • The Liver Institute at Methodist Dallas Medical CenterDallas, United States
  • University of Texas Southwestern Medical CenterDallas, United States
  • Henry Ford HospitalDetroit, United States
  • Duke Health - Duke University Medical CenterDurham, United States
  • Galen Medical GroupHixson, United States
  • Houston Methodist HospitalHouston, United States
  • Liver Associates of TexasHouston, United States
  • Southern Therapy and Advanced Research LLCJackson, United States
  • Florida Research InstituteLakewood Rch, United States
  • Cedars-Sinai Medical CenterLos Angeles, United States
  • Northwell HealthManhasset, United States
  • University of Miami - Schiff Center for Liver DiseasesMiami, United States
  • Science 37, Inc (Remote-homebased Telemedicine)Morrisville, United States
  • Vanderbilt University Medical CenterNashville, United States
  • Columbia University Medical Center - Presbyterian Hospital and Vanderbilt ClinicNew York, United States
  • New York University Langone HealthNew York, United States
  • Weill Cornell Medical CollegeNew York, United States
  • Bon Secours Liver Institution of Hampton Roads Mary Immaculate Hospital OfficeNewport News, United States
  • Einstein Healthcare Network - Einstein Medical CenterPhiladelphia, United States
  • University of Pittsburgh Medical CenterPittsburgh, United States
  • Richmond Community Hospital LLCRichmond, United States
  • Mayo ClinicRochester, United States
  • University of Rochester Medical Center - Strong Memorial HospitalRochester, United States
  • University of California - DavisSacramento, United States
  • University of Utah Health CareSalt Lake City, United States
  • California Pacific Medical Center Research InstituteSan Francisco, United States
  • Liver Institute NorthwestSeattle, United States
  • University of Washington - Harborview Medical CenterSeattle, United States
  • Tampa General HospitalTampa, United States
  • MedStar Georgetown University HospitalWashington D.C., United States

About the trial

What the trial wants to find out

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.

The 5 groups in the trial

  • Part 1 Arm 1: Volixibat 20mgTreatment being tested

    Participants randomized to this arm will receive volixibat 20mg twice daily.

    Treatment: Volixibat

  • Part 1 Arm 2: Volixibat 80mgTreatment being tested

    Participants randomized to this arm will receive volixibat 80mg twice daily.

    Treatment: Volixibat

  • Part 1 Arm 3: PlaceboPlacebo, for comparison

    Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.

    Treatment: Placebo

  • Part 2 Arm 1: Volixibat Selected Dose 20mgTreatment being tested

    Participants randomized to this arm will receive volixibat 20mg twice daily.

    Treatment: Volixibat

  • Part 2 Arm 2: PlaceboPlacebo, for comparison

    Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Record updated
19 October 2026